Full upcoming catalyst calendar

603 upcoming events · verified as of 2026-09-20 · soonest first.

All · Readouts · AdComm · Recent approvals

DateEventCompanyDrugOfficial source & verification
2026-09-21
in 1d
ESTIMATED
READOUT
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
Phase 3 · Recurrent Pericarditis
CRDL Cardiol Therapeutics Inc. CardiolRx ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-22
in 2d
ESTIMATED
READOUT
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and i
Phase 1/2 · Solid Tumor, Melanoma
ImmVira Pharma Co. Ltd T3011, T3011 + pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-22
in 2d
ESTIMATED
READOUT
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Mono
Phase 2 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
ONC BeOne Medicines Ltd. Sonrotoclax, Zanubrutinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-22
in 2d
ESTIMATED
READOUT
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 an
Phase 1/2 · Norovirus Acute Gastroenteritis
ModernaTX, Inc. mRNA-1403, mRNA-1405 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-23
in 3d
ESTIMATED
READOUT
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Ad
Phase 2 · Liposarcoma, Prostate Cancer
PFE PFIZER INC PF-07220060, Letrozole, Fulvestrant, Mid ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-23
in 3d
CONFIRMED
ADCOM
Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee
Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee
Molecular and Clinical Genetics Pa AdComm review Federal Register (FDA notice) ↗
✓ Source-checked 2026-09-20
Scheduled FDA meeting date
2026-09-24
in 4d
ESTIMATED
READOUT
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323
Phase 1/2 · Systemic Lupus Erythematosus, Lupus Nephritis
NVS NOVARTIS AG YTB323 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-27
in 7d
ESTIMATED
READOUT
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe
Phase 3 · Lupus Erythematosus, Systemic
BIIB BIOGEN INC. Litifilimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-28
in 8d
ESTIMATED
READOUT
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous
Phase 2 · Cutaneous Squamous Cell Carcinoma
INCY INCYTE CORP INCB099280 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-28
in 8d
ESTIMATED
READOUT
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Phase 2 · Amyloidosis; Systemic
Attralus, Inc. AT02 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-28
in 8d
ESTIMATED
READOUT
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Di
Phase 2/3 · Stargardt Disease
OCGN Ocugen, Inc. OCU410ST ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-28
in 8d
ESTIMATED
READOUT
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcu
Phase 3 · Hidradenitis Suppurativa
MLTX MoonLake Immunotherapeutics Sonelokimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-29
in 9d
ESTIMATED
READOUT
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Rela
Phase 3 · Eosinophilic Granulomatosis With Polyangiitis
GlaxoSmithKline Depemokimab, Mepolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-29
in 9d
ESTIMATED
READOUT
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Pa
Phase 2 · Asthma
SNY Sanofi Amlitelimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled
Phase 2/3 · Refractory Schizophrenia
SyneuRx International (Taiwan) Cor NaBen® ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib i
Phase 1/2 · Indolent B-Cell Non-Hodgkin Lymphoma
BioInvent International AB BI-1206, Rituximab, Acalabrutinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, RO
Phase 1/2 · Locally Advanced Solid Tumors, Metastatic Solid Tumors
TPB Turning Point Brands, Inc. Oral repotrectinib (TPX-0005) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
Linerixibat Long-term Safety, and Tolerability Study
Phase 3 · Cholestasis
GlaxoSmithKline Linerixibat ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Part
Phase 3 · Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche Entrectinib, Crizotinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe
Phase 3 · Lupus Erythematosus, Systemic
BIIB BIOGEN INC. Litifilimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Particip
Phase 3 · Stereotypical Prolonged Seizures
UCB Biopharma SRL Staccato alprazolam ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizum
Phase 3 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma
JAZZ Jazz Pharmaceuticals plc Zanidatamab, Tislelizumab, Trastuzumab, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab
Phase 3 · Non-Small Cell Lung Cancer
AZN ASTRAZENECA PLC Durvalumab, Oleclumab, Monalizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors
Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung
NVS NOVARTIS AG JDQ443, trametinib, Ribociclib, cetuxima ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Pati
Phase 1/2 · EGFR Mutant Advanced Non-small Cell Lung Cancer
J Ints Bio JIN-A02 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G
Phase 2 · Advanced NSCLC, Metastatic Lung Cancer
Mirati Therapeutics Inc. Adagrasib oral dose of 400 mg twice dail ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Phase 1/2 · Congenital Adrenal Hyperplasia
H. Lundbeck A/S Lu AG13909 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With
Phase 2 · Recurrent Wheezing, Wheezing Lower Respiratory Illness
OM Pharma SA OM-85 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are
Phase 2 · Advanced Solid Tumor
INCY INCYTE CORP INCB099280 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced S
Phase 1/2 · Advanced Solid Tumors
BMY BRISTOL MYERS SQUIBB CO BMS-986449, Nivolumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
Azeliragon in MGMT Unmethylated Glioblastoma
Phase 2 · Glioblastoma
Cantex Pharmaceuticals Azeliragon ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administer
Phase 1/2 · Amyotrophic Lateral Sclerosis
UniQure Biopharma B.V. AMT-162 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of
Phase 2 · Basal Cell Carcinoma
Stamford Pharmaceuticals, Inc. SP-002, Vismodegib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as
Phase 1/2 · Extensive Stage-small Cell Lung Cancer
Daiichi Sankyo Ifinatamab deruxtecan, Atezolizumab, Car ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osime
Phase 3 · Metastatic Non-small Cell Lung Cancer
AZN ASTRAZENECA PLC Dato-DXd, Osimertinib, Pemetrexed, Carbo ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Phase 2 · COPD
Uniquity One (UNI) Biological: Solrikitug low dose, Biologi ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cel
Phase 3 · Small Cell Lung Cancer
Hansoh BioMedical R&D Company HS-20093, Topotecan ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
An Extension and Crossover Vaccination Study on the Immune Response and Safety o
Phase 3 · Respiratory Syncytial Virus Infections
GlaxoSmithKline RSVPreF3 OA vaccine ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With R
Phase 2/3 · Diabetic Macular Edema (DME)
EyeBiotech Ltd. Ranibizumab, EYE103 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recover
Phase 2 · Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke
EIP Pharma Inc Neflamapimod ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balina
Phase 2 · Colitis Ulcerative, Crohn's Disease
SNY Sanofi balinatunfib, balinatunfib-matching plac ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Phase 1/2 · Hyperlipidemia; Mixed
ARWR ARROWHEAD PHARMACEUTICALS, I ARO-DIMERPA ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruqu
Phase 2 · Colorectal Cancer
Kahr Bio Australia Pty Ltd DSP107 + Atezolizumab, Fruquintinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-09-30
in 10d
ESTIMATED
READOUT
Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in
Phase 4 · Gingivitis, Plaque
CL COLGATE PALMOLIVE CO sodium monofluorophosphate toothpaste ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical
Phase 1/2 · Type 1 Diabetes Mellitus
Sernova Biotherapeutics Inc. Sernova Cell Pouch ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Y
Phase 3 · Systemic Juvenile Idiopathic Arthritis
LLY ELI LILLY & Co Baricitinib, Tocilizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Check
Phase 1/2 · Select Advanced Solid Tumors
IMCR Immunocore Holdings plc Brenetafusp, Brenetafusp and pembrolizum ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Phase 2 · Melanoma, Head and Neck Squamous Cell Carcinoma
Vyriad, Inc. VV1, Cemiplimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advan
Phase 1/2 · High-grade Glioma, Solid Tumor, Unspecified, Child
Laminar Pharmaceuticals LAM561 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-01
in 11d
ESTIMATED
READOUT
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta
Phase 3 · Primary Immune Thrombocytopenia
ARGX ARGENX SE efgartigimod PH20 SC ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus V
Phase 3 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc. Pirtobrutinib, Venetoclax, Rituximab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evalua
Phase 3 · Coronary Artery Disease
MedTrace Pharma A/S [O-15]-Water PET Myocardial Perfusion Im ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Phase 3 · Plaque Psoriasis
Organon and Co tapinarof cream, 1% ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-01
in 11d
ESTIMATED
READOUT
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular De
Phase 2 · Age-Related Macular Degeneration
NVS NOVARTIS AG Iptacopan (LNP023) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Phase 2 · Amyotrophic Lateral Sclerosis
CORT CORCEPT THERAPEUTICS INC Dazucorilant 300 mg, Dazucorilant 150 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · AMD, nAMD
ABBV AbbVie Inc. ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-01
in 11d
ESTIMATED
READOUT
SPEARHEAD-3 Pediatric Study
Phase 1/2 · Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)
USWM CT, LLC Afamitresgene autoleucel ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Phase 3 · Focal Onset Seizures
XENE Xenon Pharmaceuticals Inc. XEN1101 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
Phase 2 · Respiratory Distress Syndrome, Acute
GEn1E Lifesciences GEn-1124 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's
Phase 1/2 · Cushing Syndrome, Cushing Disease
Crinetics Pharmaceuticals Inc. atumelnant ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subj
Phase 2/3 · Oral Squamous Cell Carcinoma
Privo Technologies PRV211 (Intraoperative Cisplatin System) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-01
in 11d
ESTIMATED
READOUT
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in
Phase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma
Taiho Oncology, Inc. Futibatinib, Pembrolizumab, Cisplatin, 5 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study YL201 in Patients With Selected Advanced Solid Tumors
Phase 1/2 · Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co. YL201 for Injection ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Phase 2/3 · Dementia Moderate, Dementia, Mild
Actinogen Medical Xanamem ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pe
Phase 3 · Central Precocious Puberty
Debiopharm International SA Debio 4326 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-01
in 11d
ESTIMATED
READOUT
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Part
Phase 3 · Heart Failure, Systemic Inflammation
NVO NOVO NORDISK A S Ziltivekimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes
Phase 3 · Type 2 Diabetes
LLY ELI LILLY & Co Retatrutide ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory F
Phase 2/3 · Focal Epilepsy
BHVN Biohaven Ltd. BHV-7000, BHV-7000 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participant
Phase 2 · Alzheimer Disease
ABOS Acumen Pharmaceuticals, Inc. sabirnetug ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Phase 2 · Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Endeavor Biomedicines, Inc. ENV-101 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtica
Phase 3 · Chronic Spontaneous Urticaria
CLDX Celldex Therapeutics, Inc. barzolvolimab, Matching placebo ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtica
Phase 3 · Chronic Spontaneous Urticaria
CLDX Celldex Therapeutics, Inc. barzolvolimab, Matching placebo ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency
Phase 2 · Gene Mutations, Pseudoxanthoma Elasticum
Inozyme Pharma INZ-701 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver
Phase 3 · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
MIRM Mirum Pharmaceuticals, Inc. Maralixibat ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration
Phase 3 · Wet Age Related Macular Degeneration, wAMD
EYPT EyePoint, Inc. EYP-1901, Aflibercept (2.0 mg) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Prel
Phase 1/2 · Alopecia Areata (AA)
Aldena Therapeutics ALD-102 Solution ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to
Phase 2 · Eosinophilic Esophagitis
PHAT Phathom Pharmaceuticals, Inc Vonoprazan ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Partici
Phase 2 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH IMVT-1402 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participan
Phase 2 · Hypertension, Uncontrolled Hypertension
VNDA Vanda Pharmaceuticals Inc. iloperidone ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study to Assess Anktiva in Patients With Long Covid-19.
Phase 2 · Long COVID
IBRX ImmunityBio, Inc. N-803 (IL-15 Superagonist) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Co
Phase 3 · Congenital Pseudarthrosis of Tibia
Novadip Biosciences NVD003, Iliac Crest Bone Graft ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study Evaluating TRIV-509 in Atopic Dermatitis
Phase 2 · Atopic Dermatitis
Triveni Bio TRIV-509 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With
Phase 2 · Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V. KYN-5356 low dose, KYN-5356 Medium Dose, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-01
in 11d
ESTIMATED
READOUT
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Heal
Phase 1/2 · Norovirus
COCP Cocrystal Pharma, Inc. CDI-988, Snow Mountain Virus ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europ
Phase 3 · Neuromuscular Agents, Peripheral Nervous System Agents
Merz Aesthetics GmbH NT 201, NT 201 Placebo ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uvei
Phase 2 · Non-infectious Anterior Uveitis
Novaliq GmbH Tacrolimus ophthalmic solution ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on
Phase 2 · Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Qlaris Bio, Inc. QLS-111 Ophthalmic Solution (0.015%), QL ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Study of DISC-0974-201 in Participants With IBD and Anemia
Phase 2 · Inflammatory Bowel Disease (IBD), Anemia
IRON Disc Medicine, Inc. DISC-0974 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Di
Phase 2 · Type 2 Diabetes
Housey Healthcare ULC HP-211 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Fu
Phase 4 · Dry Eye Disease (DED)
Andover Research Eye Institute Preservative Free Polyethylene glycol 40 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10 (month)
in 11d
ESTIMATED
READOUT
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treat
Phase 2 · Forehead Lines
ABBV AbbVie Inc. AGN-151586 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-01
in 11d
CONFIRMED
ADCOM
Vaccines and Related Biological Products Advisory Committee
Vaccines and Related Biological Products Advisory Committee
Vaccines and Related Biological Pr AdComm review Federal Register (FDA notice) ↗
✓ Source-checked 2026-09-20
Scheduled FDA meeting date
2026-10-02
in 12d
ESTIMATED
READOUT
Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atro
Phase 4 · Spinal Muscular Atrophy
Genentech, Inc. Risdiplam ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-02
in 12d
ESTIMATED
READOUT
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Le
Phase 1/2 · Leptomeningeal Metastasis
CNSY CERENOME, INC. 186RNL ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-02
in 12d
ESTIMATED
READOUT
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
TAK TAKEDA PHARMACEUTICAL CO LTD TAK-861 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-05
in 15d
ESTIMATED
READOUT
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polyc
Phase 3 · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Swedish Orphan Biovitrum Pacritinib, Physician's Choice medicatio ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-05
in 15d
ESTIMATED
READOUT
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 3
Phase 1/2 · Epstein-Barr Virus Infection
ModernaTX, Inc. mRNA-1189 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-05
in 15d
ESTIMATED
READOUT
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis As
Phase 3 · Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Brist KarXT ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-05
in 15d
ESTIMATED
READOUT
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Seve
Phase 2/3 · Generalized Myasthenia Gravis
UCB Biopharma SRL rozanolixizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-06
in 16d
ESTIMATED
READOUT
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Part
Phase 3 · Idiopathic Pulmonary Fibrosis
BMY BRISTOL MYERS SQUIBB CO BMS-986278, BMS-986278 Placebo ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-07
in 17d
ESTIMATED
READOUT
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥
Phase 3 · Atopic Dermatitis
REGN REGENERON PHARMACEUTICALS, I Dupilumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-07
in 17d
ESTIMATED
READOUT
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants
Phase 1/2 · RSV Respiratory Syncytial Virus
AZN ASTRAZENECA PLC AZD6489, Licensed RSV vaccine #1, Licens ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-08
in 18d
ESTIMATED
READOUT
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participant
Phase 2 · Renal Cell Carcinoma
Hoffmann-La Roche Tobemstomig, Tiragolumab, Pembrolizumab, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-09
in 19d
ESTIMATED
READOUT
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W
Phase 3 · Hidradenitis Suppurativa
INCY INCYTE CORP Ruxolitinib Cream, Vehicle Cream ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-09
in 19d
ESTIMATED
READOUT
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W
Phase 3 · Hidradenitis Suppurativa
INCY INCYTE CORP Ruxolitinib Cream, Vehicle Cream ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-10
in 20d
ESTIMATED
READOUT
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Phase 3 · Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmace HDM1002 200 mg, HDM1002 400 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-12
in 22d
ESTIMATED
READOUT
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and H
Phase 3 · Paroxysmal Nocturnal Hemoglobinuria
REGN REGENERON PHARMACEUTICALS, I Ravulizumab, Pozelimab, Cemdisiran, Ecul ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-12
in 22d
ESTIMATED
READOUT
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-98634
Phase 1/2 · Multiple Myeloma
BMY BRISTOL MYERS SQUIBB CO CC-92480, Tazemetostat, BMS-986158, Tram ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-12
in 22d
ESTIMATED
READOUT
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Particip
Phase 3 · Metastatic Castrate-sensitive Prostate Cancer
Janssen Research & Development, LL Apalutamide, Androgen-deprivation Therap ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-13
in 23d
ESTIMATED
READOUT
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Cli
Phase 1/2 · Canavan Disease
Aspa Therapeutics AAV9 BBP-812 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-13
in 23d
ESTIMATED
READOUT
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With
Phase 2 · Idiopathic Pulmonary Fibrosis
Daewoong Pharmaceutical Co. LTD. DWN12088 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-13
in 23d
ESTIMATED
READOUT
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants
Phase 1/2 · Melanoma, Hodgkin Lymphoma
GlaxoSmithKline Cobolimab, Dostarlimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-14
in 24d
ESTIMATED
READOUT
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (
Phase 3 · Chronic Rhinosinusitis With Nasal Polyps
SNY Sanofi Itepekimab (SAR440340), Mometasone furoa ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-14
in 24d
ESTIMATED
READOUT
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1
Phase 3 · Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets
Inozyme Pharma INZ-701 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-15
in 25d
ESTIMATED
READOUT
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
Phase 1/2 · Duchenne Muscular Dystrophy
SLDB Solid Biosciences Inc. SGT-001 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-15
in 25d
ESTIMATED
READOUT
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients
Phase 2 · Ovarian Neoplasm Epithelial, Ovarian Cancer
CanariaBio Inc. Oregovomab, Paclitaxel, Carboplatin ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-15
in 25d
ESTIMATED
READOUT
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk
Phase 3 · Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LL Milvexian ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-15
in 25d
ESTIMATED
READOUT
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Phase 1/2 · Diabetic Macular Edema
Eclipse Life Sciences, Inc. EC-104 high dose, EC-104 low dose, Dexam ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-15
in 25d
ESTIMATED
READOUT
An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combin
Phase 2 · Metastatic Castration Resistant Prostate Cancer (mCRPC)
NVS NOVARTIS AG AAA617, ARPI: Abiraterone, ARPI: Enzalut ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-15
in 25d
ESTIMATED
READOUT
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
Phase 2 · Adult Obesity, Weight Management
Eccogene ECC4703, Semaglutide ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-16
in 26d
ESTIMATED
READOUT
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Ve
Phase 1/2 · Non-Hodgkins Lymphoma
Hoffmann-La Roche Glofitamab, Atezolizumab, Obinutuzumab, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-18
in 28d
ESTIMATED
READOUT
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients Wit
Phase 2/3 · Type 2 Diabetes
Han Xu, M.D., Ph.D., FAPCR, Medica Farxiga® (dapagliflozin) + Onglyza® (sax ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-19
in 29d
ESTIMATED
READOUT
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Phase 4 · Asthma
AZN ASTRAZENECA PLC Benralizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-19
in 29d
ESTIMATED
READOUT
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Plac
Phase 3 · Systemic Lupus Erythematosus
BMY BRISTOL MYERS SQUIBB CO Deucravacitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-19
in 29d
ESTIMATED
READOUT
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Com
Phase 3 · Systemic Lupus Erythematosus
BMY BRISTOL MYERS SQUIBB CO Deucravacitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-19
in 29d
ESTIMATED
READOUT
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclit
Phase 2 · Breast Cancer
Hoffmann-La Roche Tobemstomig, Pembrolizumab, Nab-Paclitax ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-19
in 29d
ESTIMATED
READOUT
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop
Phase 2 · Atopic Dermatitis
PFE PFIZER INC PF-07275315, PF-07264660 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-19
in 29d
ESTIMATED
READOUT
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant
Phase 3 · Prurigo Nodularis
INCY INCYTE CORP Povorcitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-19
in 29d
ESTIMATED
READOUT
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant
Phase 3 · Prurigo Nodularis
INCY INCYTE CORP Povorcitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-20
in 30d
ESTIMATED
READOUT
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Sym
Phase 2/3 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
BIIB BIOGEN INC. Litifilimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-20
in 30d
ESTIMATED
READOUT
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Phase 1/2 · Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo DS-3939a ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-20
in 30d
ESTIMATED
READOUT
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With
Phase 3 · Atopic Dermatitis
LEO Pharma Tralokinumab + TCS ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-20
in 30d
ESTIMATED
READOUT
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Partic
Phase 4 · Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche Faricimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-20
in 30d
ESTIMATED
READOUT
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participan
Phase 3 · Schizophrenia
Otsuka Pharmaceutical Development SEP-363856 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-22
in 1mo
ESTIMATED
READOUT
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multi
Phase 3 · Progressive Multiple Sclerosis (PMS)
Hoffmann-La Roche Ocrelizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-22
in 1mo
ESTIMATED
READOUT
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifa
Phase 1/2 · Renal Cell Carcinoma
Merck Sharp & Dohme LLC Belzutifan, Palbociclib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-22
in 1mo
ESTIMATED
READOUT
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndro
Phase 3 · Sjögren's Syndrome (SS)
AMGN AMGEN INC Dazodalibep ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-23
in 1mo
ESTIMATED
READOUT
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combinati
Phase 2 · Carcinoma, Non-Small-Cell Lung
AZN ASTRAZENECA PLC Durvalumab, Tremelimumab, Pemetrexed, Pe ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-26
in 1mo
ESTIMATED
READOUT
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodulari
Phase 3 · Prurigo Nodularis
Galderma R&D Nemolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-26
in 1mo
ESTIMATED
READOUT
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Additio
Phase 3 · Coronary Artery Disease
NVS NOVARTIS AG Inclisiran sodium 300 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-27
in 1mo
ESTIMATED
READOUT
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticance
Phase 2 · Hepatocellular Carcinoma, Biliary Tract Cancer
AZN ASTRAZENECA PLC Volrustomig, Bevacizumab, Lenvatinib, Ri ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-28
in 1mo
ESTIMATED
READOUT
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With
Phase 2/3 · Spinal Muscular Atrophy (SMA)
Hoffmann-La Roche RO7204239, Risdiplam ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-28
in 1mo
ESTIMATED
READOUT
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus
Phase 3 · Carcinoma, Renal Cell
Merck Sharp & Dohme LLC Belzutifan, Pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-28
in 1mo
ESTIMATED
READOUT
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevi
Phase 3 · Biliary Atresia
Albireo, an Ipsen Company Odevixibat ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-28
in 1mo
ESTIMATED
READOUT
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-rela
Phase 2 · Macular Degeneration, Age-related, Geographic Atrophy
Boehringer Ingelheim BI 771716, Pegcetacoplan ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-29
in 1mo
ESTIMATED
READOUT
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in P
Phase 3 · Primary Immune Thrombocytopenia (ITP)
NVS NOVARTIS AG Ianalumab, Corticosteroids ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-29
in 1mo
ESTIMATED
READOUT
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Phase 2 · Post-Bariatric Hypoglycemia
RECORDATI GROUP Pasireotide Diaspartate ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease T
Phase 2 · Gaucher Disease Type 1, Gaucher Disease Type 3
Genzyme, a Sanofi Company venglustat (GZ402671), imiglucerase ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumo
Phase 1/2 · Solid Tumor, Adult
Nouscom SRL GAd-209-FSP low dose, MVA-209-FSP low do ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrol
Phase 3 · Melanoma
PFE PFIZER INC Encorafenib, Binimetinib, Pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients
Phase 3 · Breast Cancer
Laekna Limited Afuresertib, Afuresertib/placebo ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Thera
Phase 3 · Cystic Fibrosis
Vertex Pharmaceuticals Incorporate VX-121/TEZ/D-IVA ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL
Phase 2 · Advanced Cancer, Metastatic Cancer
Mirati Therapeutics Inc. Adagrasib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G
Phase 1/2 · Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) TSN1611, TSN1611, TSN1611, TSN1611 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Phase 1/2 · Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Antelope Surgical Solutions, Inc AS1986NS ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
18F-mFBG Imaging for Myocardial Sympathetic Innervation
Phase 2 · Heart Failure, Ischemic Cardiomyopathy
Innervate Radiopharmaceuticals LLC 18F-metaFluorobenzylguanidine, Rubidium- ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-30
in 1mo
ESTIMATED
READOUT
18F-mFBG Cardiac Uptake With Lewy Body Dementia
Phase 2 · Parkinson Disease (PD), Lewy Body Dementia (LBD)
Innervate Radiopharmaceuticals LLC 18F-MFBG ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Phase 1/2 · Carcinoma, Non-Small-Cell Lung
TAK TAKEDA PHARMACEUTICAL CO LTD TAK-788 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-re
Phase 1/2 · Prostate Cancer Metastatic
ORN Orion Group Holdings Inc ODM-208, Midazolam ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participan
Phase 3 · Muscular Dystrophy, Duchenne
SRPT Sarepta Therapeutics, Inc. Eteplirsen ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAK TAKEDA PHARMACEUTICAL CO LTD TAK-788, Pemetrexed, Cisplatin, Carbopla ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic So
Phase 1/2 · Advanced/Metastatic Solid Tumors
ADAG Adagene Inc. ADG126, Pembrolizumab (KEYTRUDA®) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischem
Phase 2 · Congestive Heart Failure
AskBio Inc AB-1002 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advan
Phase 3 · Breast Cancer, Advanced Breast Cancer
OLMA Olema Pharmaceuticals, Inc. Palazestrant, Fulvestrant, Anastrozole, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol
Phase 3 · Asthma
Teva Branded Pharmaceutical Produc TEV-56248, Albuterol sulfate ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
Study of JK07 in Patients With Chronic Heart Failure
Phase 2 · Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Salubris Biotherapeutics Inc JK07 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections o
Phase 3 · Geographic Atrophy
ANNX Annexon, Inc. Vonaprument ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalen
Phase 2 · Chronic Lymphocytic Leukemia
Genentech, Inc. Venetoclax, cBTKi Monotherapy ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC
Phase 2 · MTAP-deleted NSCLC
AMGN AMGEN INC anvumetostat ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study to Investigate LP352 in Children and Adults With Developmental and Epile
Phase 3 · Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals LP352 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Phase 2 · Prader-Willi Syndrome, Obesity
RYTM RHYTHM PHARMACEUTICALS, INC. Setmelanotide ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study of SPY072 in Rheumatic Disease
Phase 2 · Rheumatoid Arthritis, Psoriatic Arthritis
SYRE Spyre Therapeutics, Inc. SPY002-072 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
Phase 1/2 · Glioblastoma (GBM)
Myosin Therapeutics Inc. MT-125 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological
Phase 3 · Relapsing Multiple Sclerosis
TG Therapeutics, Inc. Ublituximab, Ublituximab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory La
Phase 2 · Premature Ejaculation
Kadence Bio KH-001 ODT ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-10-31
in 1mo
ESTIMATED
READOUT
Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal
Phase 2 · Vaginal Dysbiosis
Freya Biosciences ApS FB-301, Chlorhexidine (0.5%) Vaginal Cle ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharma
Phase 1/2 · Leukemia, Myeloid, Acute, Refractory AML
Aptose Biosciences Inc. Tuspetinib, Venetoclax Oral Tablet, Azac ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Wa
Phase 2 · Colorectal Cancer Stage II, Colorectal Cancer Stage III
BNTX BioNTech SE RO7198457 intravenous (IV), Observationa ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
Phase 3 · Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
MCUJF MEDICURE INC Pyridoxal Phosphate ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-01
in 1mo
ESTIMATED
READOUT
Study of BBP-418 in Patients With LGMD2I
Phase 2 · LGMD2I
ULS UL Solutions Inc. BBP-418 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax
Phase 2 · Chronic Lymphocytic Leukemia (CLL)
ABBV AbbVie Inc. Venetoclax, Obinutuzumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Comb
Phase 1/2 · Relapsed/Refractory Multiple Myeloma
ONC BeOne Medicines Ltd. Sonrotoclax, Dexamethasone, Carfilzomib, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participant
Phase 1/2 · B-cell Malignancy, Marginal Zone Lymphoma
ONC BeOne Medicines Ltd. Tacabrutideg ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patien
Phase 3 · Gastro-enteropancreatic Neuroendocrine Tumor
Camurus AB CAM2029, Octreotide LAR, Lanreotide ATG ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-01
in 1mo
ESTIMATED
READOUT
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Sy
Phase 3 · Lennox Gastaut Syndrome
Epygenix Clemizole HCl ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age
Phase 3 · Partial Epilepsy
SK Life Science, Inc. Xcopri ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients
Phase 3 · Multiple Sclerosis
IMUX IMMUNIC, INC. IMU-838 tablets ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients W
Phase 3 · Multiple Sclerosis, Relapsing-Remitting
IMUX IMMUNIC, INC. IMU-838 tablets ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients W
Phase 3 · Atherosclerotic Cardiovascular Disease
NAMS NewAmsterdam Pharma Co N.V. Obicetrapib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Fo
Phase 2 · High Grade Ovarian Cancer, Primary Peritoneal Cancer
ABBV AbbVie Inc. Mirvetuximab soravtansine, Carboplatin ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/2 · Advanced Solid Tumor, Non Small Cell Lung Cancer
Anbogen Therapeutics, Inc. ABT-101 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Ca
Phase 1/2 · Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
TYRA Tyra Biosciences, Inc. TYRA-300 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Posit
Phase 2 · Metastatic Breast Cancer
Stemline Therapeutics, Inc. Elacestrant ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Can
Phase 2 · Breast Neoplasms, Invasive Breast Cancer
ATOS ATOSSA THERAPEUTICS, INC. (Z)-endoxifen, goserelin ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-01
in 1mo
ESTIMATED
READOUT
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Pr
Phase 3 · Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3
SRRK Scholar Rock Holding Corp Apitegromab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Tre
Phase 1/2 · Krabbe Disease
Forge Biologics, Inc FBX-101 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraveno
Phase 2 · Hepatocellular Carcinoma
ABBV AbbVie Inc. Budigalimab, Livmoniplimab, Lenvatinib, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and B
Phase 2 · Metastatic Colorectal Cancer, CRC
CRDF Cardiff Oncology, Inc. Onvansertib, FOLFIRI, Bevacizumab, FOLFO ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Phase 2 · NSCLC, Breast Cancer
MediLink Therapeutics (Suzhou) Co. YL202 should be intravenously infused ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate
Phase 3 · Non Muscle Invasive Bladder Cancer, Urologic Cancer
CGON CG Oncology, Inc. Cretostimogene Grenadenorepvec, n-dodecy ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Phase 2 · Pulmonary Sarcoidosis
Xentria, Inc. XTMAB-16 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Hea
Phase 2 · Cystic Fibrosis
ReCode Therapeutics RCT2100, RCT2100, RCT2100, Ivacaftor ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatom
Phase 2 · Dermatomyositis, Myositis
ARGX ARGENX SE Empasiprubart IV ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow
Phase 2 · Progressive Supranuclear Palsy
Ferrer Internacional S.A. FNP-223 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study Evaluating APG777 in Atopic Dermatitis
Phase 2 · Atopic Dermatitis
Apogee Therapeutics, Inc. APG777 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Phase 2 · Dyslipidemias
NAMS NewAmsterdam Pharma Co N.V. obicetrapib 10 mg + obicetrapib/evolocum ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Leniolisib for Immune Dysregulation in PIDs
Phase 2 · Primary Immunodeficiency Disorders (PIDs)
Pharming Technologies B.V. Leniolisib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-01
in 1mo
ESTIMATED
READOUT
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Phase 1/2 · Solid Tumor
CRBP Corbus Pharmaceuticals Holdi CRB-601 monoclonal antibody, Anti-PD-1 m ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutini
Phase 2 · Chronic Lymphocytic Leukemia
ONC BeOne Medicines Ltd. Sonrotoclax, Zanubrutinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults
Phase 3 · Obesity
LLY ELI LILLY & Co Retatrutide, Tirzepatide ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
Phase 2 · Idiopathic Pulmonary Fibrosis
Calluna Pharma AS CAL101 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-01
in 1mo
ESTIMATED
READOUT
Tirbanibulin for Pediatric Warts
Phase 4 · Warts Hand
The Skin Center Dermatology Group Tirbanibulin ointment 1% ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With I
Phase 2 · Idiopathic Hypersomnia
ALKS Alkermes plc. ALKS 2680 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932
Phase 2 · Generalized Anxiety Disorder (GAD)
ABBV AbbVie Inc. ABBV-932, Antidepressant Therapy (ADT) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab
Phase 3 · Relapsing Multiple Sclerosis
Sandoz CYB704, Ocrevus-EU, Ocrevus-US ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful O
Phase 2 · Osteoarthritis (OA) of the Knee
PCRX Pacira BioSciences, Inc. Enekinragene Inzadenovec (PCRX-201) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 D
Phase 3 · Type 1 Diabetes, Obesity
LLY ELI LILLY & Co Tirzepatide ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-01
in 1mo
ESTIMATED
READOUT
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic
Phase 3 · Bipolar-I Disorder With Mania or Mania With Mixed Features
BMY BRISTOL MYERS SQUIBB CO KarXT ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and
Phase 3 · Type 1 Diabetes, Obesity
LLY ELI LILLY & Co Tirzepatide ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Phase 2 · Hidradenitis Suppurativa (HS)
ZURA Zura Bio Ltd Tibulizumab Dose A, Tibulizumab Dose B ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medic
Phase 2 · Adjustment Disorder
Reunion Neuroscience Inc RE104 for Injection ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Ye
Phase 3 · Allergy, Peanut Allergy
DBVT DBV Technologies S.A. DBV712 250 mcg ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase
Phase 2 · Gout, Gouty Arthritis
Arthrosi Therapeutics AR882 75 mg, XOI Low Dose, XOI High Dose ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infec
Phase 2 · Viral Hepatitis
VIR Vir Biotechnology, Inc. Tobevibart, Elebsiran, Bulevirtide ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated Wit
Phase 2 · Diabetes Mellitus, Type 2
LLY ELI LILLY & Co LY3938577, Degludec ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
A Study of LY4515100 in Participants With Pain Following Third Molar Removal
Phase 2 · Acute Pain, Molar
LLY ELI LILLY & Co LY4515100 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
READOUT
To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established
Phase 3 · Plaque, Dental, Gingivitis
CL COLGATE PALMOLIVE CO Colgate SNaP Total 10/10, 1.5 Taurate, C ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-02
in 1mo
ESTIMATED
READOUT
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
Phase 2 · Neoplasms, Rectal
GlaxoSmithKline Dostarlimab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-02
in 1mo
ESTIMATED
READOUT
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adult
Phase 3 · Cutaneous Lupus Erythematosus
AZN ASTRAZENECA PLC Anifrolumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-02
in 1mo
ESTIMATED
READOUT
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-
Phase 2 · Melanoma
REGN REGENERON PHARMACEUTICALS, I cemiplimab, Fixed Dose Combination (FDC) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-02
in 1mo
ESTIMATED
READOUT
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic
Phase 3 · Bipolar Disorder Type I With Mania or Mania With Mixed Features
BMY BRISTOL MYERS SQUIBB CO KarXT ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-03
in 1mo
ESTIMATED
READOUT
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy,
Phase 3 · Chronic Spontaneous Urticaria
NVS NOVARTIS AG LOU064 (blinded) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-05
in 2mo
ESTIMATED
READOUT
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A o
Phase 3 · Hemophilia
Genzyme, a Sanofi Company Fitusiran ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-05
in 2mo
ESTIMATED
READOUT
Pediatric Long-Term Follow-up and Rollover Study
Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma
NVS NOVARTIS AG dabrafenib, trametinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-05
in 2mo
ESTIMATED
READOUT
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig
Phase 2 · B-Cell Malignancies
INCY INCYTE CORP Parsaclisib, parsaclisib + itacitinib, p ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-06
in 2mo
ESTIMATED
READOUT
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With
Phase 2 · Hodgkin Lymphoma
Merck Sharp & Dohme LLC pembrolizumab, doxorubicin, vinblastine, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-06
in 2mo
ESTIMATED
READOUT
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (
Phase 3 · Chronic Rhinosinusitis With Nasal Polyps
SNY Sanofi Itepekimab (SAR440340), Mometasone furoa ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-09
in 2mo
ESTIMATED
READOUT
A Platform Study of Novel Immunotherapy Combinations in Participants With Previo
Phase 2 · Lung Cancer, Non-Small Cell
GlaxoSmithKline Pembrolizumab, Dostarlimab, Belrestotug, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-11
in 2mo
ESTIMATED
READOUT
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuz
Phase 3 · Breast Cancer; HER2-positive; Metastatic
AZN ASTRAZENECA PLC Trastuzumab deruxtecan, Taxane, Pertuzum ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-11
in 2mo
ESTIMATED
READOUT
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metast
Phase 2 · Cervical Cancer, HPV-Related Carcinoma
PGEN PRECIGEN, INC. PRGN-2009 plus Pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-13
in 2mo
ESTIMATED
READOUT
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi
Phase 1/2 · Advanced Solid Tumors
REGN REGENERON PHARMACEUTICALS, I REGN7075, Cemiplimab, Platinum-based dou ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-13
in 2mo
ESTIMATED
READOUT
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compar
Phase 3 · Breast Cancer
Hoffmann-La Roche Inavolisib, Fulvestrant, Alpelisib, Bupr ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-13
in 2mo
ESTIMATED
READOUT
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i
Phase 2 · Overweight or Obesity
REGN REGENERON PHARMACEUTICALS, I Olatorepatide ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-15
in 2mo
ESTIMATED
READOUT
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
Phase 4 · Sciatica Acute, Lumbar Spinal Stenosis
Primus Pharmaceuticals Metaxalone 640 mg Oral Tablet ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-15
in 2mo
ESTIMATED
READOUT
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Gla
Phase 2 · Glaucoma, Open-Angle, Ocular Hypertension
PolyActiva Pty Ltd PA5108 Ocular Implant low dose, PA5108 O ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-16
in 2mo
ESTIMATED
READOUT
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Gener
Phase 2/3 · Generalized Myasthenia Gravis
UCB Biopharma SRL Zilucoplan ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-17
in 2mo
ESTIMATED
READOUT
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer
AZN ASTRAZENECA PLC AZD0901, 5-Fluorouracil, Leucovorin, l-l ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-17
in 2mo
ESTIMATED
READOUT
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemo
Phase 4 · Haemophilia A (Moderate or Severe), Hemophilia, Classic
Swedish Orphan Biovitrum Efanesoctocog alfa ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-18
in 2mo
ESTIMATED
READOUT
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polym
Phase 2/3 · Small Cell Lung Cancer
Han Xu, M.D., Ph.D., FAPCR, Medica ETOPOSIDE - Usual, ETOPOSIDE - Study ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11-18
in 2mo
ESTIMATED
READOUT
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucl
Phase 2/3 · Prostate Cancer
Han Xu, M.D., Ph.D., FAPCR, Sponso Abiraterone - Usual, Abiraterone - Study ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.